X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MERCK LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA MERCK LTD SANOFI INDIA/
MERCK LTD
 
P/E (TTM) x 39.4 48.4 81.5% View Chart
P/BV x 8.5 7.3 116.4% View Chart
Dividend Yield % 1.1 0.4 274.0%  

Financials

 SANOFI INDIA   MERCK LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
MERCK LTD
Dec-16
SANOFI INDIA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs4,5601,060 430.2%   
Low Rs4,400623 706.3%   
Sales per share (Unadj.) Rs1,028.5632.4 162.6%  
Earnings per share (Unadj.) Rs129.045.7 282.1%  
Cash flow per share (Unadj.) Rs186.062.3 298.5%  
Dividends per share (Unadj.) Rs68.0011.00 618.2%  
Dividend yield (eoy) %1.51.3 116.1%  
Book value per share (Unadj.) Rs753.6388.8 193.8%  
Shares outstanding (eoy) m23.0316.60 138.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.3 327.4%   
Avg P/E ratio x34.718.4 188.7%  
P/CF ratio (eoy) x24.113.5 178.4%  
Price / Book Value ratio x5.92.2 274.7%  
Dividend payout %52.724.1 219.1%   
Avg Mkt Cap Rs m103,17413,969 738.6%   
No. of employees `0003.61.6 228.9%   
Total wages/salary Rs m3,5921,487 241.6%   
Avg. sales/employee Rs Th6,537.76,631.9 98.6%   
Avg. wages/employee Rs Th991.4939.2 105.6%   
Avg. net profit/employee Rs Th819.8479.4 171.0%   
INCOME DATA
Net Sales Rs m23,68610,498 225.6%  
Other income Rs m708242 292.1%   
Total revenues Rs m24,39410,741 227.1%   
Gross profit Rs m5,2811,135 465.2%  
Depreciation Rs m1,313276 476.6%   
Interest Rs m150-   
Profit before tax Rs m4,6611,102 422.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691343 492.6%   
Profit after tax Rs m2,970759 391.4%  
Gross profit margin %22.310.8 206.2%  
Effective tax rate %36.331.1 116.5%   
Net profit margin %12.57.2 173.5%  
BALANCE SHEET DATA
Current assets Rs m15,6736,410 244.5%   
Current liabilities Rs m6,6788,828 75.6%   
Net working cap to sales %38.0-23.0 -164.8%  
Current ratio x2.30.7 323.3%  
Inventory Days Days7658 131.7%  
Debtors Days Days2238 58.1%  
Net fixed assets Rs m8,0981,406 575.8%   
Share capital Rs m230166 138.7%   
"Free" reserves Rs m17,0886,286 271.8%   
Net worth Rs m17,3566,455 268.9%   
Long term debt Rs m00-   
Total assets Rs m25,4008,828 287.7%  
Interest coverage x311.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 78.4%   
Return on assets %11.88.6 136.7%  
Return on equity %17.111.8 145.5%  
Return on capital %26.917.1 157.8%  
Exports to sales %24.58.3 295.7%   
Imports to sales %28.021.0 133.0%   
Exports (fob) Rs m5,801869 667.2%   
Imports (cif) Rs m6,6272,209 300.0%   
Fx inflow Rs m7,145959 745.2%   
Fx outflow Rs m6,8462,612 262.1%   
Net fx Rs m299-1,653 -18.1%   
CASH FLOW
From Operations Rs m3,2261,070 301.4%  
From Investments Rs m-1,555-750 207.4%  
From Financial Activity Rs m-1,818-150 1,213.6%  
Net Cashflow Rs m-147171 -86.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 51.8 116.6%  
Indian inst/Mut Fund % 14.4 18.2 79.1%  
FIIs % 14.6 1.0 1,460.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 29.1 36.1%  
Shareholders   15,184 28,591 53.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   TTK HEALTHCARE  ALEMBIC LTD  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

BIOCON LTD share price has hit an all time high at Rs 696 (up 1.4%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.4%) and SANOFI INDIA (up 2.6%). The top losers include TORRENT PHARMA (down 0.1%) and AUROBINDO PHARMA (down 0.2%).

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 24, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - LUPIN LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS